Working… Menu

IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03175978
Recruitment Status : Active, not recruiting
First Posted : June 5, 2017
Last Update Posted : October 23, 2020
Information provided by (Responsible Party):
IGF Oncology, LLC

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : September 2021